Lykos Therapeutics had asked the FDA to approve the drug as Component of a treatment regimen, presented along with chat therapy. those people who are pregnant or nursing will also be excluded. These limitations are more limiting than they would be for an FDA acceptance, As outlined by Betty Aldworth, the director of communications at MAPS. People